Group 1 - The core viewpoint of the news highlights the performance and investment trends of the Tianhong Innovation Drug ETF (517380) and the Biopharmaceutical ETF (159859), indicating a positive inflow of funds into these ETFs [1][2] - As of September 15, the Tianhong Innovation Drug ETF (517380) has seen a net inflow of over 120 million yuan in the past six days, while the Biopharmaceutical ETF (159859) has attracted over 220 million yuan in the last five days [1][2] - The Tianhong Innovation Drug ETF (517380) is noted as the largest ETF in the market that spans the Shanghai, Shenzhen, and Hong Kong markets, tracking the Hang Seng Shanghai-Shenzhen-Hong Kong Innovation Drug Selected 50 Index, which covers both A-shares and Hong Kong stocks [1] Group 2 - The Biopharmaceutical ETF (159859) closely tracks the National Securities Biopharmaceutical Index, which selects the top 30 stocks in the biopharmaceutical sector based on market capitalization and liquidity, reflecting the overall performance of the biopharmaceutical industry [2] - According to CITIC Securities, the performance of sub-sectors such as innovative drugs, CXO, and biopharmaceuticals has shown recovery, indicating that China's pharmaceutical industry has gained global competitiveness [2] - CICC expresses optimism about the long-term development of the innovative drug industry, noting that domestic innovative drugs have transitioned from following trends to achieving FIC/BIC innovation, entering a new phase of qualitative improvement [2]
生物医药ETF（159859）较日内低位回升超1%，创新药ETF天弘（517380）连续6日“吸金”，机构：看好创新药板块下半年机遇
2 1 Shi Ji Jing Ji Bao Dao·2025-09-16 07:05